John-Joseph Borg

List of Publications by Year
in descending order

13	161	1937685 4	1281871 11
papers	citations	h-index	g-index

13	13	13	157
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improving the data quality of spontaneous ADR reports: a practical example from Malta. Expert Opinion on Drug Safety, 2022, 21, 253-268.	2.4	4
2	The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. Drug Discovery Today, 2022, , .	6.4	4
3	Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia. Drug Discovery Today, 2022, , .	6.4	0
4	Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU. Expert Opinion on Drug Safety, 2021, 20, 815-826.	2.4	5
5	Aducanumab for Alzheimerâ€™s disease: A regulatory perspective. Pharmacological Research, 2021, 171, 105754.	7.1	40
6	Optimising bench science to withstand regulatory scrutiny. Pharmacological Research, 2019, 139, 491-493.	7.1	2
7	Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agencyâ€™s Committee for Medicinal Products for Human Use. AAPS PharmSciTech, 2018, 19, 489-511.	3.3	8
8	A review of the National pharmacovigilance system in Malta â€“ implementing and operating a pharmacovigilance management system. Expert Opinion on Drug Safety, 2017, 16, 65-76.	2.4	3
9	Changing paradigms in bioequivalence trials submitted to the EMA for evaluation â€“ A clinical and regulatory perspective. Saudi Pharmaceutical Journal, 2017, 25, 280-289.	2.7	3
10	Comment On: â€œEUâ€™s New Pharmacovigilance Legislation: Considerations for Biosimilarsâ€. Drug Safety, 2014, 37, 123-124.	3.2	1
11	Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?. Drug Safety, 2011, 34, 187-197.	3.2	78
12	Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 181.	2.1	12
13	QT shortening: a proarrhythmic safety surrogate measure or an inappropriate indicator of it?. Current Medical Research and Opinion, 0, , 1-30.	1.9	1